Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
Health Economics, Xian Janssen, Beijing, China.
J Comp Eff Res. 2017 May;6(3):205-218. doi: 10.2217/cer-2016-0086. Epub 2016 Dec 20.
To assess the cost-effectiveness of infliximab-containing therapy (ICT) for moderate-to-severe rheumatoid arthritis (RA) in a medium-sized Chinese city.
A Chinese prospective cohort study comparing ICT (25 patients) versus conventional disease-modified antirheumatic drugs (24 patients) for RA was used to assess the cost-effectiveness of ICT.
The cohort study observed significantly reduced disease activity score of 28 joints (coefficient -2.718, p < 0.001), improved EQ-5D (coefficient 0.453, p < 0.001) and increased medical costs (coefficient 1.289, p < 0.001) associated with ICT. The incremental cost-effectiveness ratio per gained quality-adjusted life year for ICT versus disease-modified antirheumatic drugs was 1.897-times of the local gross domestic product per capita.
Infliximab was a favorable cost-effective alternative option for moderate-to-severe RA in a medium-sized city of China.
评估在中国中型城市中度至重度类风湿关节炎（RA）中采用英夫利昔单抗为基础的治疗（ICT）的成本效益。
采用中国前瞻性队列研究，比较 ICT（25 例患者）与传统疾病修饰抗风湿药物（24 例患者）治疗 RA，评估 ICT 的成本效益。
队列研究观察到 ICT 可显著降低 28 个关节疾病活动评分（系数-2.718，p<0.001）、改善 EQ-5D（系数 0.453，p<0.001）和增加医疗费用（系数 1.289，p<0.001）。ICT 与疾病修饰抗风湿药物相比，每获得一个质量调整生命年的增量成本效益比为当地人均国内生产总值的 1.897 倍。
在中国中型城市中度至重度 RA 中，英夫利昔单抗是一种有利的具有成本效益的替代选择。
